ASH 2010 Conference Coverage

Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)

A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.

Utilizing home therapy for cancer-related lymphedema can lower costs

Home use of pneumatic compression devices to treat lymphedema can reduce annual treatment costs.

Drug combination produces good response rates in advanced papillary renal cell carcinoma (pRCC)

Patients with advanced papillary renal cell carcinoma (pRCC) have shown good response to a combination of two existing anticancer drugs, according to recent research.

Breast cancer and pregnancy: Overlapping of two disciplines

Oncology nurses must anticipate a disciplinary crossover between oncology and obstetrics to care for this unique subgroup of women with breast cancer.

IDH1 mutation inhibitor first to demonstrate anticancer activity

The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.

Wide variation exists in the quality and content of clinical cancer guidelines

A review of top clinical guidelines for rectal cancer shows a variety of treatment recommendations.

More open discussions when referring patients for symptoms suspicious of cancer

Patients should be more knowledgeable about suspicions of cancer when referred for follow-up care by primary care physicians.

Bowel cancer screening less likely with low numeracy skills

Those who have trouble understanding numbers may be less likely to undergo screening for bowel cancer.

Trastuzumab improves survival for HER2-positive breast cancer

Trastuzumab improved overall survival in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Increased selenium levels associated with reduced risk of colorectal cancer

Increased levels of selenium have been associated with a lower risk of colorectal cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs